Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Truist Securities analyst Danielle Brill initiated coverage on Maze Therapeutics Inc (NASDAQ:MAZE) with a Buy rating and announced a price target of $68. Maze Therapeutics shares closed at $50.39 on Tuesday. See how other analysts view this stock.
- Clear Street analyst Kaveri Pohlman initiated coverage on Evommune Inc (NYSE:EVMN) with a Buy rating and announced a price target of $53. Evommune Therapeutics shares closed at $25.03 on Tuesday. See how other analysts view this stock.
- Truist Securities analyst Danielle Brill initiated coverage on Climb Bio Inc (NASDAQ:CLYM) with a Buy rating and announced a price target of $17. Climb Bio shares closed at $7.12 on Tuesday. See how other analysts view this stock.
- B. Riley Securities analyst Mayank Mamtani initiated coverage on Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) with a Buy rating and announced a price target of $22. Arcturus Therapeutics shares closed at $6.39 on Tuesday. See how other analysts view this stock.
- Truist Securities analyst Danielle Brill initiated coverage on Apogee Therapeutics Inc (NASDAQ:APGE) with a Hold rating and announced a price target of $83. Apogee Therapeutics shares closed at $69.85 on Tuesday. See how other analysts view this stock.
Considering buying EVMN stock? Here’s what analysts think:
Photo via Shutterstock
Login to comment